GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
1k
c/glp1science·posted 10 months ago by u/aa_analysis_andy

[Discussion] we are measuring mechanism at the wrong time and calling it noise

Discussion Well Actually ×7 Clean Column ×2

we are measuring mechanism at the wrong time and calling it noise, and I am aware this is a minority view on this board.

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.

1,115 up / 82 down93% upvoted57 commentsid wtei3y3 Sep 2025

57 comments

28 in this archive, depth 5

best — the order this archive was captured in

u/employer_carveout-27 points·10 months ago

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

replysharereportpermalink
u/ferran_dahlberg1 point·10 months ago

Cosigning on GIP. The genuinely interesting thing is that the biology is not settled and the clinical result is nonetheless robust.

replysharereportpermalink
u/osman_eriksen1 point·10 months ago

Same view. Tolerance developing to the gastric effect while the appetite effect persists explains most of what the side-effect board reports.

replysharereportpermalink
u/titration_marshalmod · c/semaglutide1 point·10 months ago·edited

Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.

replysharereportpermalink
u/emil_agyeman1 point·10 months ago

Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.

replysharereportpermalink
u/aa_analysis_andyOP1 point·10 months ago

GIP is the arm people argue about because the biology is genuinely unsettled

replysharereportpermalink
u/the_poster_in_question_20262 points·10 months ago

receptor distribution is why the side effects are where they are

replysharereportpermalink
u/emil_agyeman1 point·10 months ago

GIP is the arm people argue about because the biology is genuinely unsettled

aa_analysis_andy is right that mechanism gives direction and not magnitude. Worth pinning.

replysharereportpermalink
u/second_week_sceptic115 points·10 months ago

What was the exposure in that experiment relative to therapeutic?

replysharereportpermalink
u/farid_kuipers63 points·10 months ago

Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.

replysharereportpermalink
u/santiago_rasmussen51 points·10 months ago

Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.

replysharereportpermalink
load more comments (7) →
u/milos_vanhecke79 points·10 months ago

Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.

replysharereportpermalink
u/kavya_kravchenko19 points·10 months ago

GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.

replysharereportpermalink
u/enzo_danquah37 points·10 months ago

Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.

replysharereportpermalink
u/rohan_steiner55 points·10 months ago

incretin effect first, then everything else in this board makes sense

replysharereportpermalink
u/aleksi_lehtinen15 points·10 months ago

gastric emptying slows, it does not stop

replysharereportpermalink
u/second_week_sceptic5 points·10 months ago

albumin binding is most of the half-life story

replysharereportpermalink
u/flair_enthusiast3 points·10 months ago

That conflates receptor affinity with clinical potency. They are related and they are not the same thing.

replysharereportpermalink
u/aa_analysis_andyOP2 points·10 months ago·edited

What does the discussion section say about the limitation you are glossing?

replysharereportpermalink
u/aa_analysis_andyOP20 points·10 months ago

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.

replysharereportpermalink
u/noor_hovland9 points·10 months ago

the peripheral and central stories are not in competition

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.